The latest manuscript of the INGRESS Real-world data analysis team published addressed the treatment of German focal epilepsy patients – Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.
Based on a claims dataset with a total of 34,422 patients diagnosed with FE aged 16 year or older (mean age 59.6 years, 48.7% female), the authors concluded that the percentage of prevalent patients diagnosed with FE who received one AED (monotherapy) was stable over the recent years (2007-2015) and ranged between a minimum of 66.2% (2007) and a maximum of 68.9% (2010). The percentage of patients who received two AEDs ranged from 23.6% (2012) to 25.8% (2007). The remaining patients received therapies with three (6.0% in 2010 to 6.7% in 2007), four (1.0% in 2010 to 1.2% in 2009) or more than four AEDs (0.1% in 2014 to 0.3% in 2013). Between 8.1%–16.6% (2007; 2014) of the patients received no AED therapy in the observed period.
The analysis of the patients receiving novel AEDs by the time from the first confirmed diagnosis of FE until the prescription of a novel AED resulted in a mean duration of 3.6-5.7 years, depending on the observed novel AED. Novel AEDs were prescribed in a small proportion of patients (<6%) and relatively late in the treatment course.
Detailed information is available here.